Beneficial effects of the Src inhibitor, dasatinib, on breakdown of the blood-retinal barrier
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Kim, So Ra | - |
dc.contributor.author | Suh, Wonhee | - |
dc.date.available | 2019-03-08T09:38:04Z | - |
dc.date.issued | 2017-02 | - |
dc.identifier.issn | 0253-6269 | - |
dc.identifier.issn | 1976-3786 | - |
dc.identifier.uri | https://scholarworks.bwise.kr/cau/handle/2019.sw.cau/4880 | - |
dc.description.abstract | Src kinase signaling is important in the regulation of microvascular barrier function and endothelial hyperpermeability. This study was designed to evaluate the protective effect of dasatinib, a potent Src inhibitor used clinically for the treatment of cancer, against the breakdown of the blood-retinal barrier (BRB) and the retinal vascular leakage caused by vascular endothelial growth factor (VEGF) and diabetes. We examined the effects of dasatinib on VEGF-induced endothelial hyperpermeability and the loss of vascular endothelial (VE)-cadherin, an endothelial junctional protein. Dasatinib inhibited VEGF-induced phosphorylation of Src in human retinal microvascular endothelial cells (HRMECs). In vitro and in vivo vascular permeability assays showed that dasatinib blocked the VEGF-enhanced hyperpermeability of HRMECs and decreased VEGF-mediated retinal vascular leakage in mice. Immunofluorescent staining of VE-cadherin showed that dasatinib abolished the junctional disappearance of VE-cadherin in VEGF-treated HRMECs and murine retinal vasculature. In addition, we examined the protective effect of dasatinib against diabetes-induced retinal vascular leakage in streptozotocin-induced diabetic rats. An intravitreal injection of dasatinib substantially inhibited the development of hyperpermeable retinal vasculature. Our results indicate that dasatinib is a promising agent for the prevention and treatment of diabetes-induced retinal vascular leakage. | - |
dc.format.extent | 7 | - |
dc.language | 영어 | - |
dc.language.iso | ENG | - |
dc.publisher | PHARMACEUTICAL SOC KOREA | - |
dc.title | Beneficial effects of the Src inhibitor, dasatinib, on breakdown of the blood-retinal barrier | - |
dc.type | Article | - |
dc.identifier.doi | 10.1007/s12272-016-0872-z | - |
dc.identifier.bibliographicCitation | ARCHIVES OF PHARMACAL RESEARCH, v.40, no.2, pp 197 - 203 | - |
dc.identifier.kciid | ART002196337 | - |
dc.description.isOpenAccess | N | - |
dc.identifier.wosid | 000395065900007 | - |
dc.identifier.scopusid | 2-s2.0-85006354961 | - |
dc.citation.endPage | 203 | - |
dc.citation.number | 2 | - |
dc.citation.startPage | 197 | - |
dc.citation.title | ARCHIVES OF PHARMACAL RESEARCH | - |
dc.citation.volume | 40 | - |
dc.type.docType | Article | - |
dc.publisher.location | 대한민국 | - |
dc.subject.keywordAuthor | Dasatinib | - |
dc.subject.keywordAuthor | Diabetes | - |
dc.subject.keywordAuthor | Blood retinal barrier | - |
dc.subject.keywordAuthor | Leakage | - |
dc.subject.keywordPlus | ENDOTHELIAL GROWTH-FACTOR | - |
dc.subject.keywordPlus | PROLIFERATIVE DIABETIC-RETINOPATHY | - |
dc.subject.keywordPlus | VASCULAR-PERMEABILITY | - |
dc.subject.keywordPlus | MOLECULAR-BASIS | - |
dc.subject.keywordPlus | MACULAR EDEMA | - |
dc.subject.keywordPlus | VE-CADHERIN | - |
dc.subject.keywordPlus | PHOSPHORYLATION | - |
dc.subject.keywordPlus | ANGIOGENESIS | - |
dc.subject.keywordPlus | KINASES | - |
dc.subject.keywordPlus | DISEASE | - |
dc.relation.journalResearchArea | Pharmacology & Pharmacy | - |
dc.relation.journalWebOfScienceCategory | Chemistry, Medicinal | - |
dc.relation.journalWebOfScienceCategory | Pharmacology & Pharmacy | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.description.journalRegisteredClass | kci | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
84, Heukseok-ro, Dongjak-gu, Seoul, Republic of Korea (06974)02-820-6194
COPYRIGHT 2019 Chung-Ang University All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.